Hey @Chaya just been contemplating over the last couple hours your reply to @Glitterati
Your suggestion is that the list should be (in order of release)
- OSA Trial - Left field announcement - Dow/Nasdaq Listing - Details of 2nd Psychedelics trial
Pondering the left-field announcement you said should be followed by the OAS Trial could that be interpreted to mean that we could expect a "left field announcement" that relates to OSA? Is that the reason you suggested it should follow the OAS Trial release?
I wonder what the Board would need to be contemplating at the moment in preparation of some success in the OSA Trial. Apart from Joel's previous announcements stating that a positive OSA result would be an "inflection point for the IHL share price"?
Just Brain Storming here for a minute!!! Maybe I am over thinking your comment to Glitts today but....
> Wouldn't the Board need to consider another trial? > Perhaps access to IHL-42X via the Special Access Scheme, would that be possible? > Perhaps longer-term distribution / partnerships / licensing agreements? > Would it be too far fetched to perhaps come to an agreement with RESMED who obviously have a lot at stake? ( This BOD - Answer - No! )
If you were on the BOD what would you be considering right now if you were getting positive feedback regarding the IHL-42X trial?
What could the "Left field announcement" be?
I am purely speculating here.....
GLTAH
IHL Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held